CDKN2A and MTAP Co-Deletion: Understanding the 9p21 Region
CDKN2A and MTAP lie close together on chromosome 9p21. Large or focal deletions can encompass both genes, linking cell-cycle regulation with a metabolic enzyme in one copy-number event.
Quick Answer
CDKN2A and MTAP lie close together on chromosome 9p21. Large or focal deletions can encompass both genes, linking cell-cycle regulation with a metabolic enzyme in one copy-number event.
A Neighbouring-Gene Event
Because the genes are adjacent, a deletion can remove CDKN2A and MTAP together. This is different from proving that each gene has the same biological role in that tumour.
Research Versus Routine Interpretation
MTAP-loss biology supports active research into synthetic-lethal strategies. Research rationale is not the same as an established indication, so current study and regulatory context remain essential.
Key Takeaways
- ·CDKN2A and MTAP can be co-deleted at 9p21.
- ·Copy-number reports should retain their exact wording.
- ·Emerging biomarker hypotheses need clinical validation.
Put these genes in pathway context
Frequently asked questions
What is the key idea in CDKN2A and MTAP Co-Deletion: Understanding the 9p21 Region?
CDKN2A and MTAP lie close together on chromosome 9p21. Large or focal deletions can encompass both genes, linking cell-cycle regulation with a metabolic enzyme in one copy-number event.
What should be kept with the result or mechanism?
CDKN2A and MTAP can be co-deleted at 9p21. Copy-number reports should retain their exact wording. Emerging biomarker hypotheses need clinical validation.
References
Continue Reading
MTAP Deletion and PRMT5: A Metabolic Synthetic Lethality
3 min read
CDKN2A: Two Tumor Suppressors from One Locus
4 min read
RB1 Loss in Cancer: Cell-Cycle Biology and Testing
2 min read
TP53, RB1, CDKN2A and MDM2: Tumour-Suppressor Pathways Compared
6 min read
CDK4/6 Inhibitors in Breast Cancer
4 min read
DNA Methylation in Cancer: Silencing and Instability
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
CDKN2A has 40+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.